|
|
Article: Tequin Gets FDA Approval For Short Course Treatment.
- Article from:
- TB & Outbreaks Week
- Article date:
- December 11, 2001
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 DEC 11 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Co. (BMY) has announced that Tequin (gatifloxacin), a broad-spectrum fluoroquinolone antibiotic, has been approved by the U.S. Food and Drug Administration for a short-course (five-day) regimen in the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB). Tequin is already approved for ABECB, acute sinusitis and community-acquired pneumonia.
"We are very impressed that, in our research, Tequin has been shown to be effective in treating acute exacerbation of chronic bronchitis in just five days," commented Mark H. Gotfried, MD, FCCP, Pulmonary Associates, Phoenix, Arizona. Gotfried ...